N-(4-ethylphenyl)-2-methylbenzamide | 22978-58-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-ethylphenyl)-2-methylbenzamide
• CAS: 22978-58-1
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: RYJAAXQTOOUYRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对甲苯甲酸 、 1-乙基-4-异氰基苯 在 potassium phosphate 、 palladium(II) trifluoroacetate 、 silver carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以97%的产率得到N-(4-ethylphenyl)-2-methylbenzamide
  参考文献：
  名称：

  钯催化羧酸与异氰化物脱羰偶联合成酰胺

  摘要：

  在 PdII/AgI/碱催化条件下，由羧酸和异氰化物合成酰胺。优化了反应条件，研究了反应范围。各种羧酸和芳基异氰化物与该反应相容，但烷基异氰化物不相容。提出了一种可能的机制来解释该反应，该机制具有独特的 PdII 介导的脱羰偶联和羧酸盐对 PdII 连接异氰化物的前所未有的亲核攻击。

  DOI：

  10.1002/ejoc.201300982

文献信息

• Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20070032533A1

  公开（公告）日：2007-02-08

  The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种一氧化氮增强的血管紧张素II拮抗剂化合物或其药用盐的组合物和试剂盒，以及包含至少一种一氧化氮增强的血管紧张素II拮抗剂化合物的新型组合物，还可以包含至少一种一氧化氮增强化合物和/或至少一种治疗剂。该发明还提供了用于(a)治疗心血管疾病；(b)治疗肾血管疾病；(c)治疗糖尿病；(d)治疗由氧化应激导致的疾病；(e)治疗内皮功能障碍；(f)治疗由内皮功能障碍引起的疾病；(g)治疗肝硬化；(h)治疗子痫前症；(j)治疗骨质疏松症；(k)治疗肾病；(l)治疗外周血管疾病；(m)治疗门静脉高压症；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；和(q)治疗高脂血症的方法。一氧化氮增强的血管紧张素II拮抗剂化合物包括至少一种一氧化氮增强基团，通过碳、氧和/或氮等一个或多个位点与血管紧张素II拮抗剂化合物连接，连接方式是通过一种不能水解的键或基团。
• Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20090012057A1

  公开（公告）日：2009-01-08

  The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.
• ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE
  申请人：Garvey David S.

  公开号：US20090215838A1

  公开（公告）日：2009-08-27

  The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.
• US3937840A
  申请人：——

  公开号：US3937840A

  公开（公告）日：1976-02-10
• US3985804A
  申请人：——

  公开号：US3985804A

  公开（公告）日：1976-10-12